Trials / Completed
CompletedNCT06581796
Pepsinogen-1 Serum Levels in Hyperemesis Gravidarum
Examination of the Maternal Serum Pepsinogen-1 in Patients Diagnosed With Severe Hyperemesis Gravidarum: A Prospective Case-control Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Ankara Etlik City Hospital · Other Government
- Sex
- Female
- Age
- 21 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
In this study, the investigators planned to investigate maternal serum pepsinogen-1 (MSPG-1) levels in pregnant women with severe hyperemesis gravidarum (HG) and pregnant women without severe HG. HG is the most common cause of hospitalization in the first trimester of pregnancy and represents an economic burden on the healthcare system. Therefore, our aim in this study was to investigate whether there is a statistical difference in MSPG-1 levels between pregnant women with severe HG and pregnant women without severe HG and to determine a cut-off value for MSPG-1 levels for the indication of hospitalization of pregnant women with HG. The study poses no risk to the pregnant woman or the fetus.
Detailed description
The study will enroll pregnant women in the first trimester with maternal age between 21 and 35 years who were diagnosed with hyperemesis gravidarum and had no fetal congenital or chromosomal abnormalities and who were admitted to the perinatology outpatient clinic of Etlik City Hospital. The investigators will include 40 cases with no signs and diagnosis of systemic maternal disease and no chronic drug use as a case group and 40 healthy pregnant women matched for age, gestational week and body mass index as a control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | pepsinogen-1 | association between pepsinogen 1 serum level with hyperemesis gravidarum |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2024-09-10
- Completion
- 2024-11-21
- First posted
- 2024-09-03
- Last updated
- 2024-11-27
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06581796. Inclusion in this directory is not an endorsement.